Analyst Price Targets — CLRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 2:54 pm | Jonathan Aschoff | Roth Capital | $11.00 | $3.42 | TheFly | Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital |
| March 28, 2024 7:33 am | Jeff Jones | Oppenheimer | $12.00 | $3.64 | StreetInsider | Cellectar Biosciences (CLRB) PT Raised to $12 at Oppenheimer |
Latest News for CLRB
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26 FLORHAM PARK, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and…
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLRB.
U.S. House Trading
No House trades found for CLRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.